NRG4 and cancer: In conclusion, here we propose a provocative therapy based on the combinatorial administration of a growth factor, namely NRG4, in combination with anti-ERBB2 antibodies as a novel anti-cancer strategy based on specific activation of ERBB4-ERBB4 homodimers.